Admission Liver Injury Is an Independent Predictor of Early and Overall Mortality in Hospitalized Patients with Moderate-to-Critical COVID-19: A Retrospective Cohort Study.

Publication date: Sep 16, 2026

Background: Liver injury (LI) is frequently observed in patients with COVID-19, particularly in severe forms of disease. However, its prognostic significance remains incompletely defined. Aim: To evaluate the association between LI at admission and clinical outcomes in hospitalized patients with moderate, severe, and critical COVID-19. Methods: This single-centre retrospective cohort study included 816 adults hospitalized with moderate-to-critical COVID-19 at a tertiary care hospital in Romania. LI was defined as elevations ≥ 2cD7 the upper limit of normal (ULN) in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), or total bilirubin (TB) at admission. Clinical, laboratory, imaging, and outcome data, including intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), and mortality, were analysed. Results: LI was present in 34. 9% of patients. Compared with patients without LI, affected patients more frequently exhibited inflammatory syndrome (98. 7% vs. 95. 2%, p = 0. 017), elevated interleukin-6 (IL-6) levels (65. 3% vs. 44. 3%, p = 0. 007), and extensive pulmonary involvement (>75% on chest computed tomography; 38. 2% vs. 27. 3%, p = 0. 003). They were also more likely to require ICU admission (44. 2% vs. 36. 2%, p = 0. 025) and IMV (30. 9% vs. 23. 5%, p = 0. 011). Seven-day mortality (25. 9% vs. 16. 1%, p = 0. 001) and overall mortality (49. 8% vs. 36. 8%, p

Open Access PDF

Concepts Keywords
Basel COVID-19
Laboratory liver diseases
Liver liver function tests
Pandemic mortality
Romania prognosis
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
disease MESH included
drug DRUGBANK Alkaline Phosphatase
disease MESH ALP
disease MESH syndrome
disease MESH Emergency
disease MESH drd
drug DRUGBANK Coenzyme M
disease MESH liver diseases
disease MESH infection
disease MESH acute respiratory distress syndrome
disease MESH multiple organ failure
drug DRUGBANK Angiotensin II
disease MESH cytokine storm
disease MESH hypoxia
disease MESH hypoalbuminemia
disease MESH infectious diseases
disease MESH death
drug DRUGBANK Fibrinogen Human
drug DRUGBANK Trestolone
disease MESH IBM
disease MESH cardiovascular disease
disease MESH diabetes mellitus
disease MESH obesity
disease MESH malignancies
disease MESH rhinorrhea
disease MESH anosmia
disease MESH cough
disease MESH dyspnea
disease MESH tachypnea
disease MESH fever
disease MESH chills
disease MESH nausea
disease MESH vomiting
disease MESH ageusia
disease MESH abdominal pain
disease MESH diarrhea
disease MESH leukocytosis
disease MESH lymphopenia
disease MESH thrombocytosis
disease MESH Metabolic Syndrome

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *